NMD4C Investigators Submit Response to CDA Draft Guidance on NBS
On behalf of its Newborn Screening (NBS) Advisory Panel, Canada’s Drug Agency (CDA) recently published a discussion paper outlining its approach for developing Canadian newborn screening guidance. The goal of this discussion paper is to outline the foundations for a set of national guidelines for provincial and territorial governments to inform the development of their NBS programs. CDA have issued a call for input in response to this paper, providing an opportunity for the Canadian healthcare community to help shape the formation of these national NBS guidelines.
A group of NMD4C investigators submitted a response to this discussion paper, led by network co-lead Dr. Homira Osman, with input from neuromuscular experts including Dr. James Dowling, Dr. Hanns Lochmüller, Dr. Alex MacKenzie, Dr. Hugh McMillan, Dr. Maryam Oskoui, Dr. Kathryn Selby and Dr. Pranesh Chakraborty.
The author group noted that while the discussion paper from the CDA outlines important aspects of newborn screening, it fails to address critical issues related to infrastructure, national standards, and the integration of emerging technologies. The group identified that a broader approach is needed—one that encourages innovation, addresses systemic lab issues, and ensures equitable implementation across all provinces.
The authors recommended the creation of a national framework that sets minimum standards while allowing for the necessary flexibility to adopt new treatments and technologies as they become available. The system must be prepared for the future, and free from rigid processes that prevent timely advancements.
For any questions about future group recommendations from the network, please contact Dr. Homira Osman at .
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.